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TETRAHYDROBIOPTERIN MEDIATED MECHANISMS AND THERAPEUTIC 
APPROACHES IN COLITIS  




Significant and paramount discoveries in the past two centuries have propelled 
studying the gastrointestinal tract (GI) and brain connection to the forefront of all research. 
As the second most ranked common inflammatory disease, inflammatory bowel disease 
(IBD) is a chronic disorder of the GI tract marked by periods of relapse and remission with 
symptoms of abdominal pain, weight loss, GI bleeding, and diarrhea.  It affects as many as 
3.1 million people in the US (1.3% of the total population) and 2.2 million people in 
Europe. In addition to contributing significantly to the morbidity, mortality, and disability 
demands on the health care system, IBD also considerably diminishes the quality of life 
due to its frequent reoccurrences, low remission rate and debilitating symptomology. Due 
to its chronic intestinal inflammatory state, pain (both inflammatory and referred visceral 
pain to the abdomen) is a defining symptom of the disease activity. However, due to its 
idiopathic nature, treatment of the inflammation and pain pathologies distinct to IBD has 
been unsatisfactory.  
Among the many treatments of IBD, sulfasalazine (SSZ) is an sepiapterin reductase 
(SPR) inhibitor of the tetrahydrobiopterin (BH4) pathway. However, SSZ has a more 
modest effect and is a less potent inhibitor when compared to other known SPR inhibitors, 
such as SPRi3, of which have proven to not be ideal in humans do to lack of solubility. 
Because SSZ is used as IBD treatment and because enterochromaffin (EC) cells, located 
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mainly in the colon, produce over 90% of the body’s serotonin (5-HT), a neurotransmitter 
that requires BH4 for its synthesis, we questioned whether BH4 plays a critical role in the 
pathogenesis of IBD.  
Many studies have characterized EC cells as gate keepers to pain signaling, where 
they bridge the connection between intestinal contents and the somatosensory system 
located underneath that then connects back to the central nervous system. Our lab has 
further characterized BH4 as an essential key regulator for T-cell proliferation, a key 
mediator in IBD, by using a novel SPR inhibitor, QM385, to not only block its 
proliferation, but to also alleviate chronic pain. QM385 has the same inhibitory effects 
as SPRi3, but at a lower concentration with minimal side effects, longer half-life and 
more favorable central nervous system penetration kinetics in rodents. These 
groundbreaking findings allow us to hypothesize that BH4 plays a significant dual role 
in IBD inflammation and the resultant pain, by acting on: 1) Macrophage and T-cell 
activation and function and 2) 5-HT signaling from EC cells. Moreover, we hypothesize 
that the inhibition of BH4 with our newly created pro-drug, QM385, will reduce the 
sensory input from EC cells and the inflammatory response in IBD simultaneously.  
 
Methods 
The widely accepted DSS animal model was used to better understand the 
pathologies of pain and inflammation in IBD and to a deeper extent examine the effects of 
the QM385 treatment. Six-day 2% DSS treated mice and control were all were assessed 
for inflammation and pain using the following: disease activity index (DAI), abdominal 
hypersensitivity with von Frey filaments, colon microscopic lesions, levels of neopterin 
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(BH4 pathway synthesis biomarker) and sepiapterin (SPR inhibition biomarker) and gene 
expression for GCH1 (BH4 pathway enzyme), TNF-α (inflammatory mediator), CD68 
(macrophage marker), CD4 (T-cell marker), SPR (BH4 pathway enzyme), and TrpA1 
(nociceptive ion channel expressed on EC cells). 
 
Results/ Conclusions: 
In this study, the DSS induced IBD model in mice was successfully implemented 
evidenced by the DAI data, morphological changes, and mechanical hypersensitivity. 
DSS treatment increased mechanical hypersensitivity, clinical and morphological 
inflammatory symptoms, BH4 activity (neopterin, GCH1, SPR), inflammatory mediators 
(CD68, CD4, and TNF-α), and nociceptive receptor transcription, TRPVA1 production. 
Sepiapterin was observed after QM385 treatment, suggesting BH4 inhibition of DSS-
induced IBD. QM385’s role in alleviating the immune response in DSS-induced IBD was 
evident with the improvements in the macroscopic clinical symptoms of inflammation 
(DAI) and recovery in colon length. QM385 also demonstrated a significant improvement 
in referred visceral abdominal pain at 1 and 3 mg/kg. Moreover, QM385 appears to 
resolve the upregulation of 5-HT and GCH1 in the distal colon after DSS treatment; 
therefore, we show that QM385 suppresses the BH4 pathway in EC cells (i.e. suppress 
EC cell activation), by causing less 5-HT production and therefore, less activation of the 
gut sensory neurons. In summary, QM385 treatment alleviated the degree of colitis 
caused by DSS and the degree of inflammatory and referred visceral pain, suggesting that 
QM385 might be a novel agent for the treatment of chronic colitis as seen in IBD.  
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An Introduction to Pain 
 
The International Association for the Study of Pain (IASP), defines pain as a 
physical, biological, emotional and psychosocial multidimensional phenomenon 
experienced universally across all ages with the fundamental purpose of survival, 
adaptation and protection against damage (Belkind-Gerson and Kuo, 2015; Kansal and 
Hughes, 2016; Marchand, 2017; Mifflin and Kerr, 2014). Despite it being the most 
common reason for pursuing medical attention, treating and quantifying pain remains a 
challenge due to its multifaceted nature (Committee on Advancing Pain Research et al., 
2011. These challenges are magnified in certain diseases, such as irritable bowel disease 
(IBD), where pain loses its fundamental purpose to protect and becomes pathological and 
chronic. 
The World Health Organization and the Center for Disease Control and Prevention, 
cite chronic pain as one of the most common world health problems, with a growing 
prevalence that affects 116 million Americans, 8% of which suffer from high impact 
chronic pain. This condition contributes to a significant national economic burden of $560-
$635 billion per year due to lost productivity, disability programs, and medical costs 
(Committee on Advancing Pain Research et al., 2011; Dahlhamer et al., 2018; Mifflin and 
Kerr, 2014). In fact, pain is considered a greater economic burden than heart disease ($300 
billion), cancer (~$250 billion) and diabetes (~ $200 billion) (Biswas, 2017). Despite its 
high prevalence, chronic pain still remains both the most challenging and least understood 
medical condition (Mifflin and Kerr, 2014). 
 
2 
Types of Pain Syndromes 
An acute pain state is a normal, protective, physiological response to a noxious 
stimulus that the nervous system detects, adapts, and responds to accordingly (Marchand, 
2017). Acute pain can be mild to severe, lasting a moment to weeks or in some cases 
months until the cause of the pain is resolved (Cheng and Rosenquist, 2018). In the chronic 
state, pain loses this protective function and becomes both physically debilitating (i.e. 
limited mobility, fatigue, and disrupted sleep and appetite) and emotionally taxing (i.e. 
anxiety, depression, irritability, and anger). Chronic pain persists more than 6 months 
despite the presence or absence of a noxious stimulus (Marchand, 2017). The mechanisms 
of transition between acute to pathological pain, especially in the context of chronic 
diseases, are still not fully understood and remain at the forefront of current research. 
Understanding the different classifications of pain (nociceptive, inflammatory, 
neuropathic, and dysfunctional) and the diseases plagued by it will shed light on these 
mechanisms and provide the opportunity for treatment.  
 
Nociceptive Pain 
Nociceptive pain, an immediate and protective response to a noxious stimulus, is 
caused by the activation of primary sensory neurons in transiently damaged tissue that 
direct pain sensations to the central nervous system (Costigan et al., 2009). Examples 
include bee stings, pin pricks or stubbing a foot. This acute pain is protective and does not 





Inflammatory pain results in prolonged heightened sensitivity to previously 
innocuous low-threshold stimuli at or near the site of inflammation (Costigan et al., 2009). 
Inflammatory pain is a result of the sensitization of the primary afferent neurons due to 
inflammatory cytokines and other mediators usually released from immune cells that are 
recruited to the tissue injury site (Bielefeldt et al., 2009). The resulting activation of 
nociceptive pathways leads to hypersensitivity in neighboring non-inflamed areas 
(Costigan et al., 2009). Normally this pain is acute and adaptive, for example, by limiting 
use of an injured extremity to protect from further damage. However, if inflammation 
continues for long periods without resolving, this pain can become chronic and 
pathological with few, if any, positive side effects (Costigan et al., 2009). 
 
Neuropathic Pain 
Neuropathic pain (NP) is primarily characterized as a maladaptive response or 
neural plasticity to injury caused to any part of the nervous system and, in most cases, 
presents as a chronic condition (Costigan et al., 2009). Peripheral NP results from damage 
to the peripheral nervous system from neurotoxic chemicals, metabolic diseases, 
mechanical trauma, or infection. Whereas central NP results from central nervous system 
(CNS) damage like that of a stroke or spinal cord injury (Costigan et al., 2009). 
Understanding the mechanistic causes of this longer-term maladaptive response to nerve 
injury, felt by some but not all patients with frank nerve damage, is essential for the 




Dysfunctional pain usually occurs without an identifiable cause. This sort of pain includes 
fibromyalgia, complex regional pain syndrome (CRPS), cystitis and irritable bowel 
syndrome (IBS) (Costigan et al., 2009). IBS is a common dysfunctional pain disorder that 
affects the large intestine. Signs and symptoms include cramping, abdominal pain, 
bloating, gas, and diarrhea or constipation, or both (Abdul Rani et al., 2016). Although 
similar to IBD in outward signs, this type of pain is less serious both in symptoms and 
actual signs of bowel inflammation and damage (Abdul Rani et al., 2016).  
 
Visceral Pain 
Pain can also be classified by the place it originates from. Visceral pain results from 
the activation of nociceptive sensory neurons of the thoracic, pelvic, or abdominal viscera 
(Giamberardino and Costantini, 2009; Sikandar and Dickenson, 2012). Visceral structures 
are highly sensitive to distension (stretch), ischemia and inflammation, but relatively 
insensitive to other noxious stimuli, that would normally evoke pain, such as cutting or 
burning (Giamberardino and Costantini, 2009; Sikandar and Dickenson, 2012).  
 
Prevalence 
According to IASP, visceral pain is the most common pain subtype and the most 
likely to require medical attention. Up to 25% of the global population report experiencing 
visceral pain (Elsenbruch et al., 2015). Common affected areas include pelvic pain in 16-
24% of women, chest pain in 20% of adults, and intermittent abdominal pain in 25% of 
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cases (Halder and Locke, 2009). Abdominal pain is also the most frequent diagnosis and 
the leading symptom prompting outpatient and inpatient clinic visits (Collett, 2013; Peery 
et al., 2012, 2015). However, one third of patients cannot localize or clearly identify their 
pain (Kraychete et al., 2017). This non-specific abdominal pain accounts for 67% of 
consecutive hospital admissions and £100 million of costs in the United Kingdom (UK) 
(Collett, 2013; Halder and Locke, 2009). Common causes of abdominal pain include: 
gastroenteritis (7.0-19.2%), IBS/ IBD (2.6-13.2%), urologic cause (5.3%) and gastritis 
(5.2%) (Kraychete et al., 2017). 
 
Clinical Presentations 
 Visceral pain is described as a diffuse, poorly defined, unlocalizable, constant dull 
pain sensation located in the midline of the thorax or abdomen (Giamberardino and 
Costantini, 2009; Sikandar and Dickenson, 2012). Symptoms include vomiting, sweating, 
altered heart rate and urinary frequency, nausea, and emotional reactions, such as anxiety 
(Giamberardino and Costantini, 2009). Pain emanating from the heart, gallbladder, 
pancreas or stomach will be perceived as diffuse internal pain as well as non-organ-specific 
hypersensitivity. For example, a myocardial infarction can be misperceived as indigestion 
(Giamberardino and Costantini, 2009).  
Referred pain can often develop from the source of true visceral pain and in some 
cases it can be the first presentation at the onset of visceral pain (Giamberardino and 
Costantini, 2009; Sikandar and Dickenson, 2012). Referred pain often presents within the 
somatic areas of skin and muscle connected to the visceral organ, and, unlike true visceral 
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pain, it is less diffuse (Giamberardino and Costantini, 2009). It is believed that second order 
neurons within the spinal cord that process the painful visceral signals can misalign these 
inputs because the same neurons receive information from multiple body parts; 
consequently, they can send ambiguous information to the brain as to the exact location of 
the noxious stimulus (Robinson and Gebhart, 2008). While referred hyperalgesia (an 
amplified response to an already painful stimulus) occurs in many cases, allodynia (pain 
sensation to a non-painful stimulus) can occur in more severe cases (Giamberardino and 
Costantini, 2009). Pain threshold measurements of various types of stimuli (thermal, 
electrical, mechanical, and chemical) can be used to assess referred pain with hyperalgesia 
(Giamberardino and Costantini, 2009). For instance, thermal hyperalgesia can be tested 
using a heated thermal or electrical stimulator, calibrated mechanical forceps, or 
application of algogenic chemical substances (Giamberardino and Costantini, 2009). 
Referred mechanical allodynia of the abdomen, as a result of colonic inflammation, is 
usually measured by the response to fine nylon von Frey filaments or to a brush stroke, 
both of which normally would not elicit a painful response (Giamberardino and Costantini, 
2009). 
 
Irritable Bowel Disease 
 IBD (exemplified by Crohn’s disease, CD, and ulcerative colitis, UC) is an 
idiopathic inflammatory chronic disorder of the gastrointestinal (GI) tract that is clinically 
characterized by periods of relapse and remission with symptoms of abdominal pain, 
weight loss, GI bleeding, and diarrhea (Anbazhagan et al., 2018). Due to the intestinal 
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inflammation alongside IBD, pain (both inflammatory pain and referred visceral pain) is a 
defining symptom of the disease activity, where in some patients it may be the only 
presenting symptom (Bielefeldt et al., 2009). Abdominal pain (referred visceral pain) is the 
presenting symptom in 50%-70% of patients at the initial onset or worsening of IBD 
(Bielefeldt et al., 2009). However, in 20% of patients with endoscopic remission (no 
detectable colitis or inflammation), pain is still significantly present (Bielefeldt et al., 
2009). This demonstrates that the etiology of IBD pain is not exclusively due to GI 
inflammation and that there is a continuum with IBD symptoms and signs, which may also 
include the less severe symptoms of IBS (Abdul Rani et al., 2016). 
 
Prevalence 
 Ranking as the second most common inflammatory disease, IBD affects millions 
of people worldwide with the highest incidence rates in the UK, northern Europe and North 
America. It contributes significantly to the morbidity, mortality, and disability demands on 
the health care system (Loftus, 2004). As many as 3.1 million United States (US) citizens 
(1.3% of the total population) and 2.2 million European citizens are affected (Anbazhagan 
et al., 2018). Since 1999, there has also been a sizeable increase in IBD incidence of 0.9% 
in the US (2018). The incidence rate of IBD is rising and spreading to areas of the world 
where the culture is becoming more ‘Western’, such as Japan, Singapore, northern India, 
South Korea and Latina America (Loftus, 2004). This is even more alarming when some 
of the newly industrialized countries, such as China or India, exceed a population of over 
one billion people. Furthermore, IBD contributes to a considerable economic burden with 
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medically associated costs of over $6 billion in the US, £4.6-5.6 billion in Europe, and $1.2 
billion in Canada (Kaplan, 2015). This does not include non-medically related costs 
including the unmeasurable, yet massively consequential, reduced quality of life for 
patients and their families and the loss in work productivity, which ultimately exceeds 
medically related costs (Kaplan, 2015). 
 
Current IBD Therapies 
 Despite being medically recognized as early as 1761, successfully treating IBD has 
been challenging due to its unknown causes and multifactorial contributing factors (Sands, 
2007). However, the past 30 years have seen important advances in therapy (Rutgeerts, 
2004). Treatment modalities include nutritional therapy, corticosteroids, aminosalicylates, 
immunomodulators, and antibiotics (Ko and Auyeung, 2014; Rutgeerts, 2004). Among the 
most effective forms of treatment are the older pharmacological agents, such as 
sulfasalazine (SSZ) and methotrexate (MTX), as well as newer biological treatments, such 
as anti- tumor necrosis factor (TNF) neutralizing antibodies (Neurath, 2017).  
SSZ, developed in the 1940s, is currently used as an anti-inflammatory treatment 
for a number of conditions, including rheumatoid arthritis (RA), IBD and ankylosing 
spondylitis (Costigan et al., 2012). In fact, SSZ was discovered serendipitously as an IBD 
treatment when patients being treated for RA also experienced alleviation of their UC 
symptoms (Sands, 2007). It is used in treating mildly active IBD and with continual use, 
provides a low relapse rate of 12%. However, the pain usually occurs upon discontinuation, 
suggesting that SSZ is effective, but not potent enough to provide long-term relief 
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(Baumgart and Sandborn, 2007; Caprilli et al., 2009; Dignass et al., 2010). Moreover, SSZ 
is ineffective in patients with moderate to severe IBD (Baumgart and Sandborn, 2007; 
Dignass et al., 2010). In order to effectively treat the majority of active IBD and the 
induction and maintenance of remission, high doses are required. This is highly 
discouraged due to the high incidence of side-effects, including headache, nausea, vomiting 
and fever (observed in 15–20% of patients) (Caprilli et al., 2009; Dignass et al., 2010). 
Mechanistically, SSZ reduces cellular tetrahydrobiopterin (BH4) by inhibiting sepiapterin 
reductase (SPR), an enzyme in the de novo pathway (see “BH4 Pathway and Pain” section 
and Figure 1 for more details) (Yang et al., 2015). Interestingly, MTX, another IBD 
therapy, acts as a dihydrofolate reductase (DHFR) inhibitor, which lowers BH4 levels by 
inhibiting the salvage pathway (Yang et al., 2015). These two drugs implicate the treatment 
of IBD through the inhibition of BH4.  
 Biologic therapy with anti-TNF agents, such as infliximab, adalimumab, 
golimumab and certolizumab pegol, aid in suppressing intestinal inflammation present in 
IBD (Neurath, 2017). Infliximab is used for patients with moderate to severe IBD, who do 
not effectively respond to other treatments, such as SSZ (Baumgart and Sandborn, 2007). 
In the inflamed colon of IBD, TNF, a cytokine immune response mediator, is produced in 
many immune and non-immune cells, such as macrophages, T cells, dendritic cells, and 
fibroblasts (Neurath, 2017). TNF plays a considerable role during IBD-induced intestinal 
inflammation, by activating macrophages and T cells to produce proinflammatory 
cytokines (Neurath, 2017). Anti-TNF agents have been effective at curbing the actions of 
many of these intestinal inflammatory contributors (Neurath, 2017). Additionally, 
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polytherapy has been shown to be more effective (Neurath, 2017). The combined 
immunosuppression of infliximab and drugs, such as SSZ and MTX, have been shown to 
be more effective at maintaining remission and reducing the risk of adverse outcomes, as 
well as inducing regulatory macrophages with wound-healing potential (Herfarth, 2016; 
Neurath, 2017).  
 Despite these advancements, there is still a need for more effective, longer‐term 
IBD treatment that have less side effects, provide more convenient dosing regimens and 
further extend the induction and maintenance of remission (Shin et al., 2017).  
 
 Pain and IBD: Recent Research 
 Significant and paramount discoveries since the nineteenth century have propelled 
the concept of the GI-brain connection to the forefront of all research. As the largest 
exposed surfaces of the body, the intestine has been demonstrated to be one of the most 
important factors contributing to a person’s overall physical, emotional and psychological 
health (Bellono et al., 2017; Yarandi et al., 2016). With only a single layer of epithelial 
cells, with the exception of the multilayered esophagus, the intestinal epithelium provides 
a barrier between the lumen of the GI tract and the body’s visceral tissue (Bellono et al., 
2017). It monitors, integrates and processes intrinsic and extrinsic factors and accordingly 
modulates signaling pathways that control inflammation, pain and digestion (Bellono et 
al., 2017; Furness et al., 2013).  
Enterochromaffin (EC) cells are located in the crypts of the small intestine, colon 
and rectum (Grundy, 2008). Despite being less than 1% of the total intestinal epithelia, EC 
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cells play a considerable role in producing over 90% of the body’s serotonin (5-HT), which 
is released basally upon activation of EC cell luminal receptors (Furness et al., 2013). 5-
HT requires BH4 for its synthesis (see “BH4 Pathway and Pain” section) and functions in 
a variety of physiological roles within the GI tract including sensory signaling as well as 
other autonomic functions such as peristalsis (Bellono et al., 2017; Frazer and Hensler, 
1999). EC cell-derived 5-HT act on enteric neurons and immune cells throughout the body 
and contribute considerably to pathophysiological states, such as referred visceral pain and 
GI dysmotility, all of which are hallmark symptoms of IBD (Bellono et al., 2017). In some 
areas of the GI tract, such as the stomach or duodenum, EC cells have high concentrations 
of 5-HT as a protective mechanism against toxic substances (Furness et al., 2013). For 
example, EC cell-derived 5-HT can provoke vomiting and increase peristalsis by acting on 
the vagal nerve, which innervates the intestinal wall and transmits a signal to the vomiting 
centers of the brain (Breit et al., 2018; Furness et al., 2013). Interestingly, medications 
affecting 5-HT levels have been associated with peripheral intestinal effects, including a 
reduction of mechanical hypersensitivity (Bellono et al., 2017; Kun et al., 2014).  
EC cells extend from the apical surface to the basal side of the epithelial layer where 
their cytoplasmic extensions contact sensory and autonomic neurons (Wade and Westfall, 
1985). Many studies have shown that EC cells can transduce information from the 
intestines to the nervous system through the activation of its receptors, such as transient 
receptor potential ankyrin 1 (TrpA1), leading to a release of 5-HT that acts on visceral 
sensory afferents within the GI tract (Bellono et al., 2017; Breit et al., 2018). TRP receptors 
are sensory transducing receptors that covert sensory stimuli into action potentials and help 
 
12 
enable sensory perception throughout the body (Brierley et al., 2009; Furness et al., 2013). 
TrpA1 can transduce chemical sensitivity in naïve uninflamed intestinal tissue and can 
cause mechanical hypersensitivity in colitis (Brierley et al., 2009). Given this, EC cells are 
the electrically excitable gate keepers to pain signaling in the bowel - communicating 
directly from the intestinal lumen to the somatosensory system.  
 
Inflammation in IBD 
 A chronic inflammatory response, as seen in IBD, results in a prolonged heightened 
sensitivity categorized as inflammatory pain. The initial barriers of protection in the 
intestine include mucosal and epithelial layers (Choy et al., 2017). In IBD, there is 
epithelial loss resulting in increased permeability and exposure to the luminal components 
that elicit an immune response (Choy et al., 2017). A key feature of IBD is the persistent 
immune activation specifically in the innate and adaptive immune systems (Choy et al., 
2017). As of 2016, there are over 160 genetic loci related to the immune system that are 
associated with IBD (Choy et al., 2017).  
Of the many innate immune-mediated cells involved in IBD, macrophages are 
crucial to the disease’s pathogenesis and contributes to the inefficient microbe clearance 
and impairment of the transition from an early pro-inflammatory to a subsequent anti-
inflammatory response, which in an un-diseased intestine would occur during 
inflammatory resolution (Steinbach and Plevy, 2014). Large numbers of cluster of 
differentiation 68 (CD68) positive macrophages infiltrate the intestinal mucosa in IBD, 
which is reduced with treatment of infliximab (See “Current IBD Therapies” Section for 
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details) (Caprioli et al., 2013). These macrophages produce pro-inflammatory cytokines, 
such as interleukin 23 (IL-23), TNF-α and IL-6 (Cader and Kaser, 2013). The increase in 
cytokine secretion, specifically in TNF-𝛼, transforming growth factor-beta (TGF-𝛽), and 
interferon-gamma (IFN-𝛾), is commonly seen at the onset and establishment of IBD (de 
Mattos et al., 2015). TNF-𝛼 significantly contributes to the pathogenesis of IBD due to it 
increasing the expression of other inflammatory mediators (IL-1β, IL-6, and IL-33) (Lee 
et al., 2018). Moreover, the severity of IBD correlates to serum levels of TNF-𝛼 in patients 
since it is secreted by both innate (macrophages) and adaptive (T-cells) cells (Lee et al., 
2018). This is largely why anti-TNF-𝛼 agents are very effective treatments for IBD since 
they target both arms of the immune response (See “Current IBD Therapies” Section for 
details) (Smids et al., 2018; Zhang, 2014).  
 
BH4 Pathway: Pain and Inflammation 
 Many animal models of chronic pain have been utilized to identify and characterize 
the BH4 pathway and its role in chronic pain (Costigan et al., 2012; Latremoliere and 
Costigan, 2018, 2011). BH4 is an essential cofactor for the production of dopamine, 
serotonin, epinephrine, and other neural signaling molecules such as nitric oxide (Costigan 
et al., 2012). Cellular levels of BH4 are controlled by three pathways – de novo synthesis, 
salvage, and recycling pathways (Costigan et al., 2012) (Figure 1A). The de novo pathway 
feeds into the salvage pathway and the production of BH4 leads to the recycling pathway. 
In many cell types, the de novo pathway activity is tonically low with the other two 
pathways maintaining basal homeostatic BH4 levels (Costigan et al., 2012). 
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Using one of the chronic NP paradigm in rodents, the spared nerve injury (SNI) 
model (Costigan et al., 2009), our lab discovered that GTP cyclohydrolase (Gch1), Spr, 
and quinonoid-dihydrobiopeterin reductase (Qdpr) were all upregulated in sensory neurons 
with damaged axons after SNI, with Gch1 being the most significant (Tegeder et al., 2006). 
Gch1 is the rate-limiting step for the synthesis of BH4 in the de novo synthesis pathway; 
Spr is the final enzyme in the synthesis pathway and Qdpr is found in the recycling pathway 
(Costigan et al., 2012). These findings also translated to what is observed in humans 
(Costigan et al., 2012). Polymorphisms of the GCH1 gene is associated with less persistent 
pain after back surgery; this version of the GCH1 gene is present in approximately 15% of 
the Caucasian population, mainly in heterozygous form (Costigan et al., 2012; Tegeder et 
al., 2006, 2008). Furthermore, after nerve injury, people with the GCH1 haplotype 
(decreased GCH1 function) showed less upregulation of BH4 levels and felt less pain, 
suggesting that BH4 plays a major role in the pain phenotype (Tegeder et al., 2006). Since 
these findings, a link of the GCH1 haplotype with pain has been confirmed by at least ten 
independent studies (Latremoliere and Costigan, 2018). 
The association of the BH4 pathway with chronic pain is further supported using 
genetically modified strains of mice with selective mutations for Gch1. Using the Cre-lox 
technology, overexpressing Gch1 in sensory neurons resulted in an overproduction of BH4 
along with increased pain, while GCH1 knockout mice did not have elevated BH4 levels 
and were significantly less sensitive to pain (Latremoliere et al., 2015). Moreover, there 
was co-staining of Gch1 and CD68, a macrophage marker, suggesting an innate 
immunological aspect of the disease and BH4 (Costigan et al., 2012). In a different study, 
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the intraplantar injection of BH4 in mice induced nociceptive pain (Nasser et al., 2015). 
These studies further solidify the association of BH4 with pain via its involvement in the 
sensory and immune systems.  
Further analysis of the de novo pathway suggests that the inhibition of GCH1 would 
likely lead to neurological and physiological issues. Since GCH1 is the only enzyme 
capable of catalyzing the first stage of BH4 synthesis, inhibiting it too heavily will result 
in pathological run down of this essential co-factor in neurotransmitter production 
(Costigan et al., 2012) (Figure 1A). Alternative therapeutic approaches to reduce BH4 
levels are to target other enzymes. SPR is downstream of GCH1 and inhibiting it would 
allow for the production of some BH4, while still reducing over-production that can be the 
cause of chronic pain following nerve injury (Costigan et al., 2012). An effective SPR 
inhibitor would resemble the pain response of people with the GCH1 haplotype, who 
naturally do not make as much BH4 following injury and therefore feel less chronic pain. 
With an SPR inhibitor, we propose replicating this situation in chronic pain patients.  
The mechanism of SSZ remained unclear until Kai Johnson and colleagues 
demonstrated that at least part of SSZ’s action is as a SPR inhibitor, which others have 
since confirmed (Yang et al., 2015) (Figure 1B). However, SSZ has a more modest effect 
and is a less potent inhibitor when compared to other known SPR inhibitors, such as N-(2-
(5-hydroxy-2-methyl-1H-indol-3-yl)ethyl)-2-methoxyacetamide (SPRi3) (Latremoliere et 
al., 2015). In animal models of chronic pain, SPRi3 did not affect GCH1 levels and 
significantly reduced BH4 levels without eliminating all the BH4 – allowing for the basal 
homeostatic levels necessary for normal physiological functioning to persist (Costigan et 
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al., 2012). However, because of lack of solubility, SPRi3 is not ideal for use in humans 
(Latremoliere et al., 2015).  
Although inhibiting this cascade could be dangerous to health, due to its importance 
functions across multiple systems, we propose that important mechanisms can be inhibited 
successfully. The key is to strike the correct balance of inhibition in focused situations 
where the system is heavily activated, like is the case in chronic inflammatory pain diseases 
such as IBD. Proof of this is evident in other commonly used drugs. Ketamine for instance 
inhibits the NMDA receptor or Benzodiazepines modulate the GABA system, both of these 
systems are crucial to survival, however can be modulated safely, to a certain degree. 
In more recent findings in our lab, we prove that BH4 is an essential key regulator 
for T-cell proliferation (Cronin et al., 2018). This was examined using a novel SPR 
inhibitor, QM385, that simulated the same inhibitory effects as SPRi3, but at a lower 
concentration, minimizing the side effects (Cronin et al., 2018). This more modern pro-
drug compound, which was created in work related to us, also has a long half-life in 
mice allowing a daily dosing protocol and has favorable CNS penetration kinetics in 
rodents (Cronin et al., 2018). CNS penetration is not something that would be 
recommended for such compounds due to the heavy use of BH4 de novo synthesis 
cascade in serotonergic and dopaminergic neurons within the brain. Work related to this 
research is actively working to design pro-drug compounds in higher animals with low 
or absent CNS penetration, for rodents, however, QM385 is effective and has few side 
effects at very high doses (results not shown). In recently published studies QM385, in 
a dose-dependent manner, successfully reduced plasma levels of BH4 and increased 
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those of sepiapterin, which is a SPR inhibition biomarker (Cronin et al., 2018). 
Moreover, QM385 also blocked the proliferation of human CD4 T cells at low doses, 
with good bioavailability and nanomolar potency (Cronin et al., 2018). QM385 proves 
to be an effective treatment for T-cell mediated autoimmune diseases, such IBD in Rag1 
-/- mice supplemented with exogenous T cells (Cronin et al., 2018).  
 
Animal Models: The DSS-induced Colitis Model  
Many animal models of IBD are either chemically-induced, genetically-modified 
mice that develop symptoms spontaneously, or adoptive T-cell transfer models 
(Ghattamaneni et al., 2019). Over the past 25 years, the chemically-induced model, the 
most common version of which uses dextran sulfate sodium (DSS) in the animal’s drinking 
water, has become popular (Ghattamaneni et al., 2019). While no animal model exactly 
epitomizes human IBD, the DSS-induced colitis closely mimics the IBD’s symptomology 
of diarrhea, rectal bleeding, altered microbiome and intestinal epithelial damage and 
increased permeability (Ghattamaneni et al., 2019). 
The administration of 3-10% of DSS, a water-soluble negatively charged sulfated 
polysaccharide, for 6 to 10 days induced intestinal inflammation in mice that is 
morphologically and symptomatically similar to what is seen in human IBD patients 
(Okayasu et al., 1990). DSS induces intestinal inflammation by acting as a chemical toxin 
on the epithelia leading to an increase in its permeability and the entry of luminal bacteria 
and proinflammatory intestinal content into the mucosa and its underlying tissue (Eichele 
and Kharbanda, 2017). The duration, frequency and the concentration of DSS as well as 
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the mouse strain and its microbial environment (i.e. germ-free) will influence the 
effectiveness of DSS-induced colitis and determine the severity of colitis (i.e. chronic or 
acute) (Eichele and Kharbanda, 2017). The standard colitis model involves the 
administration of 2-5% DSS for 6-10 days with an average of 7 days and typically in 
C57BL/6 male mice (Eichele and Kharbanda, 2017). Mice develop diarrhea, rectal 
bleeding, weight loss, crypt abscesses in the large intestine, and multiple erosions (Okayasu 
et al., 1990). Additional changes include shorter colon length, increased epithelial 
permeability, epithelial erosion, mucin and goblet cells depletion, and infiltration of 
granulocytes into the lamina propria and submucosa, which induces an immune response 
(Eichele and Kharbanda, 2017; Sayer et al., 2002). Even one day exposure to DSS is 





Figure 1: Description of the BH4 pathway: 1A) BH4 levels are controlled by three 
pathways – de novo synthesis, salvage, and recycling pathways. The de novo pathway 
feeds into the salvage pathway. BH4 is a cofactor for other neuro-modulators such as nitric 
oxide synthase enzymes (NOS), tyrosine hydroxylase (TyrOH), tryptophan hydroxylase 
(TrpOH) and phenylalanine hydroxylase (PheOH). TrpOH produces serotonin, NOS 
produces nitric oxide – both of these have been shown to be important in IBD mechanisms. 
Enzymes along the pathways are shown in green circles: GTP cyclohydroxylase 1 (GCH1); 
6-pyruvoyl tetrahydrobiopterin synthase (PTS); sepiapterin reductase (SPR); aldose 
reductase (AR); carbonyl reductase (CR); dihydrofolate reductase (DHFR); pterin-4a-
carbinolamine dehydratase (PCBD) and quinonoid-dihydrobiopterin reductase (QDPR). 
2,4 diamino-6-hydroxypyrimidine (DAHP) and methotrexate (MTX) are inhibitors that 
lead to lower or no levels of BH4. 1B): Changes to BH4 levels. (1) In the presence of 
nerve injury, there is an increase in BH4 synthesis that lead to an increase in pain. (2) SSZ, 
an SPR inhibitor, results in lower levels of BH4 through the inhibition of the de novo 







Irritable bowel disease (IBD) is an idiopathic inflammatory chronic disorder of the 
gastrointestinal tract that is clinically characterized by periods of relapse and remission 
with symptoms such as abdominal pain, weight loss, GI bleeding, and diarrhea. We 
hypothesize that BH4 plays a significant dual role in IBD inflammation and the resultant 
pain, by acting on: 1) Macrophage and T-cell activation and function and 2) Serotonin 
signaling from Enterochromaffin (EC) cells. We hypothesize that the inhibition of BH4 
with our newly created pro-drug, QM385, will reduce the sensory input from EC cells and 
the inflammatory response in IBD simultaneously. 
Confirmation of DSS-induced IBD model: Since the clinical and pathological changes 
in DSS-induced IBD are analogous to human IBD, we will first establish the 2% DSS 
induced IBD model in our lab and evaluate the effects of the DSS administration with 
daily measurements of the clinical activity and abdominal hypersensitivity of the disease. 
Histological analysis of colon mucosa will be performed to examine inflammatory 
infiltration, epithelial loss, and crypt integrity. 
The role of BH4 in the inflammatory response of IBD:  To examine the role of EC 
cells on colon inflammation in IBD, immunohistochemistry will be used to label 
serotonin and eGFP (Gch1 expressing cells) in colons of DSS-induced IBD. Using qPCR, 
we will measure the gene expression of Gch1 and Spr of the BH4 synthesis pathway and 
inflammatory and EC / sensory cell markers. Neopterin, a biomarker for the BH4 
synthesis pathway, will be assessed in the colon using ELISA analysis. 
 
21 
The role of BH4 in the referred visceral pan response of IBD: In order to assess the 
action of BH4 signaling in abdominal pain of IBD, we will examine the effect of the Spr 
inhibitor, QM-385, on the clinical disease activity and abdominal mechanical 
hypersensitivity in DSS- induced IBD using the von Frey filaments. Plasma levels of 
sepiapterin, a biomarker of SPR inhibition by QM-385, will also be measured.  
 
We hypothesize that QM-385 inhibition will reduce pain signaling and ongoing 




MATERIALS AND METHODS 
Animals and Housing  
To assess DSS-induced IBD, adult male C57BL/6J (Jackson Laboratory) and 
eGFP- Gch1 Swiss Webster (Latremoliere et al., 2015) mice, aged 6-8 weeks, were used 
in these experiments. All mice were housed in ventilated cages (maximum five mice per 
cage) under standard pathogen-free laboratory conditions in an animal facility at Boston 
Children’s Hospital. Throughout the duration of experiments, mice had an ad libitum 
supply of standard chow diet and autoclaved water (either treated with or without DSS). 
All animal procedures and care were completed in accordance to Institutional Animal Care 
and Use Committee (IACUC) of Boston Children’s Hospital under animal protocols 18-
04-3681R. 
 
DSS-Induced IBD  
To induce IBD, mice received an ad libitum supply of 2% DSS (MP Biomedicals, 
36-5 kDa) in autoclaved water for six days followed by non-treated autoclaved water for 
the remainder of each experiment until euthanasia at either Day 7 (Figure 2) or Day 9 
(Figure 3). Control animals received non-treated autoclaved water on an ad libitum basis. 
In order to study treatment of DSS-induced IBD, DSS treated and untreated mice received 
treatment of either QM385 or vehicle via oral gavage on Days 7, 8, and 9 (Figures 3). All 
DSS-induced IBD experiments were performed in C57BL/6J mice, with the exception of 




Treatment of DSS-induced IBD 
All treatment drugs and vehicles were freshly prepared. The Spr inhibitor, QM385 
(10mg/kg, our lab), was prepared in 1% tween-80 and 0.5% sodium carboxymethyl 
cellulose (both from Sigma-Aldrich) and administered to mice by oral gavage on Days 7, 
8, and 9 (Figure 3). Doses given were 0.3, 1 and 3 mg/kg. One-hour post-treatment, testing 
for abdominal mechanical hypersensitivity was performed. 
 
 
Figure 2. Schematic Overview of DSS induced IBD. C57BL/6J mice received an ad 
libitum supply of 2% DSS (dextran sodium sulfate) in drinking water for six days followed 
by non-treated water for the remainder of each experiment. Control mice did not receive 
DSS treated water. Disease activity index (DAI) and abdominal hypersensitivity were 
assessed on Days 0-7. Biological samples (blood and colon tissue) were collected at the 




Figure 3. Schematic Overview of DSS induced IBD and IBD mice treated with 
QM385. C57BL/6J and eGFP-GCH1 mice received an ad libitum supply of 2% DSS 
(dextran sodium sulfate) in water for six days followed by non-treated water for the 
remainder of the experiment and oral treatment of QM385 on Days 7-9. Control mice did 
not receive DSS, but did receive QM385. Disease activity index (DAI) and abdominal 
hypersensitivity were assessed on Days 0, 1, 6, and 9. Biological samples (blood and colon 




Disease Activity Index Assessment of DSS-Induced IBD 
To assess the severity of DSS-induced IBD, the clinical activity of the disease was 
assessed using the Disease Activity Index (DAI). To calculate DAI, daily body weight, 
presence of gross blood in the stool (hematochezia), and stool consistency was evaluated 
and a score for each parameter was assigned using Table 1. The sum of these scores 
determined the DAI, ranging from 0 to 12 (Table 1). Colon length was determined upon 
collection at necropsy at Day 9. 
 
Table 1. Scoring system to calculate disease activity index (DAI) (adapted from 
Shon et al., 2015). 
Score Weight loss Stool consistency Hematochezia 
0 None Normal  
(well-formed pellets) 
None 
1 1–5% Soft None 
2 6–10% Very soft and unformed Occult bleeding 
3 11–15% Diarrhea Evident bleeding 
 
Abdominal Mechanical Hypersensitivity of DSS-induced IBD 
To assess chronic visceral pain in DSS-induced IBD, abdominal mechanical 
hypersensitivity was performed using a graded series of von Frey filaments (Touch Test® 
Sensory Evaluators, North Coast Medical, Morgan Hill, CA) that individually produced a 
bending force of 0.02, 0.04, 0.07, 0.16, 0.4, 0.6, 1, 1.4, 2, 4 and 6 grams, respectively. Prior 
to behavior, mice were individually acclimated for one-hour in a covered plexiglass cage 
(7.5 x 7.5 x 15 cm) with a wire mesh floor (as shown in Figure 4). Then, in ascending 
order of bending force, each filament was applied perpendicularly to the diaphragm 
territory (superior abdomen) for 3 seconds with an inter-stimulus interval of 10 seconds for 
a total of 10 times. Baseline measurements were obtained by applying all the filaments and 
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recording the number of positive responses (abdominal licking/ withdrawal upon stimulus). 
The mechanical response threshold was determined by a positive response to at least 5 of 
the 10 stimulations from the minimal bending force filament. Data was expressed as the 
mechanical response threshold average per condition.  
 
 
Figure 4: Methodology for testing abdominal mechanical hypersensitivity using von 
Frey filaments. To assess chronic visceral pain in DSS-induced IBD, abdominal 
mechanical hypersensitivity was performed using a graded series of von Frey filaments. 
Each filament was applied perpendicularly to the diaphragm territory (superior abdomen) 
as described above (Image obtained from (Deuis et al., 2017))   
 
BH4 Metabolism Assessment: Neopterin 
 To examine levels of neopterin, a biomarker for the BH4 pathway synthesis, half a 
centimeter colon sections were harvested from C57BL/6J mice on Day 7, which were 
deprived of water and food four hours prior (Figure 2). Colon tissue was then homogenized 
(1:10, w/v) in phosphate-buffered saline (pH 7.4) containing Tween 20 (0.05 %), 0.1 mM 
phenylmethylsulfonyl fluoride, 10 mM EDTA, 2 ng/mL aprotinin, and 0.1 mM 
benzemethonium chloride. After centrifugation (3,000 × g; 10 min; 4° C), the supernatant 
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was used for ELISA analysis (IBL International, Hamburg, Germany). Results were 
expressed as nmol per liter (nmol/L). 
 
Assessment of QM-385 action: Sepiapterin  
 To examine levels of sepiapterin (biomarker of SPR inhibition), on Day 9 plasma 
was taken from blood that was obtained by cardiac puncture, placed in tubes containing 
anticoaogulant (ethylenediaminetetraacetic acid, EDTA) and centrifuged (5,000 × g; 15 
min; 25° C) for component separation. Plasma was precipitated with TCA 5% + DTE 
6.5mM (1:1, v/v), centrifuged (10,000 × g; 10 min; 4° C), and analyzed with HPLC using 
an Beckman System Gold (Beckman Instruments, Inc., Fullerton, CA) with a Waters 
Atlantis dC-18, 5 μmRP column (4.6 x 250mm; 35° C) and a flow rate of 0.5 mL/minute 
and isocratic elution of mobile phase (92% phosphate buffer- 15mM, 8% acetonitrile 
(90%), pH 6.4). Results were expressed as nmol of sepiaterin per liter of plasma (nmol/L). 
 
Immunohistochemistry  
To examine the expression of serotonin and its potential role in the BH4 pathway, 
the DSS Gch1-eGFP Swiss Webster mice and its controls were euthanized by CO2 
asphyxiation on Day 9. Half a centimeter colon sections from the distal most part of the 
anus were dissected, post fixed in 4% paraformaldehyde/ phosphate buffered saline (PBS) 
for 30 minutes, cryoprotected in 30% sucrose overnight and frozen in OCT (Tissue-Tek). 
10 μm transverse cryosections were fixed again (in 4% paraformaldehyde/PBS for 30 
minutes), blocked with 10% blocking reagent (Roche)/ 5% bovine serum albumin (Sigma-
 
27 
Aldrich)/ 0.1%Triton X-100 in 0.1 M PBS for an hour, incubated with goat anti-serotonin 
(1:500, Immunostar) antibody (24 hours, overnight at 4°C), incubated again with rabbit 
anti-goat antibody Alexa Fluor 594 (1:400, Life Technologies) and mounted using 
Vectashield containing DAPI. In between each step, the sections were washed three times 
in 1x PBS (10 minutes each time). Images were obtained with the ImageXpress Micro 
Confocal High-Content Imaging System at 20X in stacks at every 1 μm. 
 
Histopathology of DSS-Induced IBD  
Distal colon sections of 0.5 cm in length was dissected, washed in saline, fixed in 
10% formalin buffer solution, dehydrated in ethanol and embedded in paraffin. Transverse 
sections (10 µm thick) were deparaffinized with xylene, stained with haematoxylin and 
eosin, and imaged under a light microscope. The microscopic score, ranging from 0 to 9, 
is the summed value of the signs of epithelial loss, crypt integrity and inflammatory 
infiltrate (Table 2) (adapted from (Akgun et al., 2005)). 
 
Table 2. Scoring system to calculate microscopic lesions 
Score Epithelial loss Crypt integrity Inflammatory infiltrate 
0 None Intact crypt None 
1 Loss < 5% Loss < 10% Mild 
2 Loss 5-10% Loss 10-20% Medium 




Quantitative real-time PCR (Q-PCR) 
Colon sections (0.5 cm from the distal most part of the anus) were harvested on 
Day 7, immediately frozen, and RNA extracted by acid phenol extraction (TRIzol 
reagent, Invitrogen). First-stranded cDNA synthesis (0.5 μg of total RNA per reaction) 
was performed using the SuperScript VILO cDNA Synthesis Kit (Invitrogen). Using the 
Sybr green detection system and relative standard curve, qPCR was performed to 
determine transcript regulation of the following primers specific for: Gch1 (BH4 pathway 
enzyme), Tnf-α (inflammatory mediator), CD68 (macrophage marker), CD4 (T-cell 
marker), Spr (BH4 pathway enzyme), and TrpA1 (nociceptive ion channel expressed on 
EC cells).  
 
Data Analysis 
 All values were expressed as means plus or minus standard error of the mean (X ± 
SEM. Statistical analysis of DAI scores was performed using repeated-measures analysis 
of variance (ANOVA) followed by Bonferroni’s multiple comparisons post-hoc test and 
by one-tailed unpaired t-test. Behavioral data were analyzed using repeated-measures 
ANOVA followed by Bonferroni’s multiple comparisons post-hoc test and by Wilcoxon 
signed rank test for column analysis. Histopathology and neopterin levels were processed 
using one-tailed unpaired t-test. qPCR data was analyzed using two tailed t-test. Statistical 
analysis of sepiapterin levels one-way ANOVA followed by Tukey's multiple comparisons 
post-hoc test. Colon length measurements was analyzed using one-way ANOVA followed 
by Newman-Keuls multiple comparisons post-hoc test. Experimental groups mostly 
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comprised 6–8 animals for in vivo observations and 4–8 animals for ex vivo 
determinations. In all tests p < 0.05 was considered significant. GraphPad Prism® software 





IBD Model Assessment: The Effect of the DSS Administration. 
Six-day 2% DSS treated mice and control were all were assessed for disease activity 
course, abdominal hypersensitivity, macroscopic lesions, levels of neopterin and gene 
expression for Gch1, Spr, TrpA1, CD68, CD4, and TNF-α.  
To evaluate the severity of colitis, DAI score was monitored daily in DSS treated 
and non-treated mice. The DAI score of both groups was 0 initially (Figure 5). In the 6-
day 2% DSS treatment group, there was a significant elevation in DAI score. On days 5, 6, 
and 7 of DSS administration, the DAI scores of the DSS group were significantly higher 
than that of control group (F(7,88)=4.09;  p<0.001). Significant IBD symptomatology was 
also evident on Day 7 in DSS-treated mice a day after DSS discontinuation (t(11)=3.339; 
p<0.01]). 
The severity of colitis on mechanical abdominal sensitivity was assessed with von 
Frey testing (Figure 6). Throughout the entirety of this experimental protocol, the control 
group did not demonstrate a significant change in the von Frey filament strength. However, 
as early as one day of DSS treatment, there was a slight difference between DSS treated 
and non-treated groups. A statistically significant difference in mechanical abdominal 
sensitivity between the two groups began to be observed on Day 2, in the early stages of 
DSS-induced IBD, and increased until Day 5, where it reached the maximum response that 
continued through the end of the experimental protocol (F(7,88)=11.16; p<0.001) (Figure 
6). The maximum mechanical sensitivity response in the DSS treated group was nearly 
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identical on Days 5, 6, and 7, represented by the lowest filament strength need to elicit a 
positive response (Figure 6).  
 The involvement of inflammatory mediators and of the BH4 pathway in IBD 
induction with DSS was measured on Day 7 using the microscopic histological damage 
score, levels of neopterin, and gene expression for Gch1, Spr, TrpA1, CD68, CD4, and 
TNF-α. The microscopic histological damage score, which assessed the microscopic 
epithelial loss, infiltration of inflammatory cells and crypt integrity, was significantly 
higher in the DSS treated group compared to control (t(8)=7.76;  p<0.001) (Figure 7). In 
the DSS treated group, there was a statistically significant upregulation of levels of 
neopterin (a BH4 synthesis pathway biomarker) in the inflamed colon (t(5)=2.51; p<0.05) 
(Figure 8). The BH4 synthesis pathway was further assessed with Gch1 and SPR gene 
expression using qPCR analysis, which in the DSS group compared to control showed a 
3.5-fold statistical increase in Gch1 gene expression and a 1.6-fold statistical increase in 
SPR gene expression (Figure 9). The immune response in DSS-induced IBD was assessed 
with the gene expression of TNF-α (cytokine immune response mediator), CD68 
(macrophage marker), and CD4 (T-cell marker), all of which showed a statistically 
significant upregulation in the DSS-treated group with a 4.2-fold increase in CD4, 3.5-fold 
increase in TNF-α and 3.4-fold increase in CD68 (Figure 9). Finally, the gene expression 
of TrpA1 (nociceptive ion channel expressed by EC cells) also showed a statistically 




Figure 5. Disease Activity Index (DAI) of DSS-Induced IBD in C57BL/6J Mice. The 
development of DSS-induced inflammation was assessed daily for 7 days with the DAI of 
DSS treated and non-treated C57BL/6J mice. DAI was determined by combined scores of 
weight loss, stool consistency and hematochezia, as indicated in Table 1. Mice treated with 
2% DSS began to show signs of the disease starting as early as Day 1 with DAI score 
changes reaching significance on Days 4 to 7, followed by partial recovery on Day 7 after 
DSS treatment was terminated. Statistical analysis included: repeated measures analysis of 
variance (ANOVA) (F(7,88)=4.09; *p<0.001) followed by Bonferroni’s multiple 




Figure 6. Abdominal Hypersensitivity of DSS-Induced IBD in C57BL/6J mice.  
Abdominal allodynia as a measure of referred mechanical hypersensitivity due to IBD in 
2% DSS treated and untreated control mice was determined using von Frey filaments with 
average values plotted. Increased abdominal hypersensitivity was evident as early as Day 
1 of DSS treatment, reaching statistical significance on Days 2-7. Statistical analysis 
includes: repeated measures analysis of variance (ANOVA) followed by Bonferroni’s 













Figure 7. Histopathology of DSS-Induced IBD in C57BL/6J mice. The colons of the 
DSS-treated (B) and untreated (A) in C57BL/6J mice were harvested on Day 7, fixed, and 
H&E stained. For C), the histopathological score (microscopic lesions) were calculated 
based on signs of epithelial loss, crypt integrity and inflammatory infiltrate (Table 2). One-
tailed unpaired t-test was done for microscopic lesions. (t(8)=7.76; p<0.001). Error bars 





Figure 8. Neopterin levels in DSS-Induced IBD in C57BL/6J mice. To define 
engagement of the BH4 synthesis cascade within inflamed mouse colon, we quantified the 
level of neopterin in the distal colon of 2% DSS treated mice. Neopterin, a biomarker for 
the BH4 synthesis pathway, is significantly upregulated in this tissue at Day 7 (Figure 2). 
One-tailed unpaired t-test was used for neopterin (t(5)=2.51; p<0.05). Error bars represent 






Figure 9. qPCR Results for Gene Expression of Gch1 and Inflammatory Markers 
in the Distal Colons of DSS Treated C57BL/6J mice. qPCR shows statistically 
significant increases in mRNA gene expression of Gch1, Spr, TrpA1, CD68, CD4, and 
TNF-α in DSS treated mice. Gch1 is upregulated over 3.6-fold in the inflamed colon; Spr 
1.6-fold; TrpA1 1.8-fold; CD68 3.4-fold; CD4 4.2-fold; TNF-α 3.5-fold. Statistical 













Drug Intervention: The Effect of QM385 Administration in DSS Induced IBD 
The effect of 3-day QM385 administration in 6-day 2% DSS treated mice and 
control were all were assessed for disease clinical course, abdominal hypersensitivity, 
sepiapterin levels, colon lengths and immunoreactivity for Gch1 and 5-HT.  
To evaluate the severity of colitis with QM385 treatment, DAI score was monitored 
daily for nine days in DSS treated and non-treated mice (Figure 10). Since early time points 
are similar to the results collected above, only data for Day 9 is shown here. While the DAI 
score of both groups was initially 0, significant IBD symptomatology was present in the 
DSS-treated mice at day 9 versus non-DSS treated nice (naïve). A non-significant 
difference between all DSS QM385 treated groups versus vehicle control was seen at day 
9. These data suggest, but do not prove, that QM385 improves DAI scores in a non-dose 
responsive manner (Figure 10).  
The effect of QM385 administration on mechanical abdominal sensitivity was 
tested with von Frey testing (Figure 11). Since early time points are similar to the results 
collected above, only data for Day 9 is shown here. At day 9, following 3 days of drug 
treatment, there was a dose responsive decrease in mechanical sensitivity in all of the 
groups treated with QM-385 relative to the DSS treated group not treated with this 
compound. This decrease in ongoing mechanical abdominal pain was statistically 
significant at 1 and 3 mg/kg QM-385 (Figure 11).  
Moreover, the severity of colitis with QM385 treatment was further evaluated by 
measuring colon length at Day 9 (Figure 12). DSS only treated colons had statistically 
decrease in the colon length compared than that of control. However, the colon length of 
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DSS treated group with QM385 (3mg/kg) showed a statistically significant increase in 
length to that of the DSS treated group with no QM385 treatment.  
The effect of QM385 on the BH4 pathway was assessed through the levels of 
plasma sepiapterin at Day 9 (Figure 13). All groups that were not treated with QM385 did 
not have a detectable level of sepiapterin. A 3-day treatment of QM-385 (0.3, 1, 3 mg/kg) 
in the DSS-treated groups demonstrated a dose responsive increase in sepiapterin levels.  
Moreover, the expression of 5-HT and Gch1 in EC cells was examined in the distal colon 
of the Gch1-eGFP Swiss Webster mice. Colon sections were stained for 5-HT in red and 








Figure 10. Disease Activity Index (DAI) in DSS induced IBD and IBD mice treated with 
QM385. To induce IBD, C57BL/6J mice received an ad libitum supply of 2% DSS in 
drinking water for 6 days followed by non-treated water for the remainder of the 
experiment until Day 9. Control (Naive) animals received non-treated water on an ad 
libitum basis. From day 7 to 9, DSS mice were treated daily by oral gavage with either 
vehicle or QM385 at the three doses (0.3, 1, 3 mg/kg), x-axis. On day 9, QM385 
demonstrated a marked but non-significant decrease in DAI scores relative to the un-treated 
mice (Vehicle). Improvements in DAI score did not demonstrate a QM385 dose 





Figure 11. Abdominal Mechanical Hypersensitivity in DSS induced IBD and IBD 
mice treated with QM385. To induce IBD, C57BL/6J mice received an ad libitum supply 
of 2% DSS in drinking water for 6 days followed by non-treated water for the remainder 
of each experiment until testing at Day 9. Control animals received non-treated water on 
an ad libitum basis. From day 7 to 9, DSS treated and untreated mice were treated daily by 
oral gavage with either vehicle or QM385 at the three doses (0.3, 1, 3 mg/kg) - x-axis. 
Mechanical hypersensitivity was determined using von Frey filaments of varying bending 
forces (0.02- 6 g). At Day 9, following 3 days of drug treatment, there was a dose 
responsive decrease in hypersensitivity at all doses of QM-385 relative to IBD mice not 
treated with this compound. This decrease in ongoing mechanical abdominal pain was 
statistically significant at 1 and 3 mg/kg QM-385. (F(12,60)=4.1444, P<0.0001). Statistical 
analysis included: repeated measures analysis of variance (ANOVA) followed by 






Figure 12. Colon Length in DSS 
induced IBD and IBD mice 
treated with QM385. Total colon 
length in control (untreated) versus 
IBD mice (vehicle) at day 9 
following 6 Days (Day 0-6) of DSS 
treatment (2%). Mice treated with 
3mg/kg QM385 (Days 7-9) showed 
statistically significantly longer 
colons at day 9 than DSS IBD mice 
(black vs. red bar). These data 
indicate that at 3mg/kg DSS this 
compound may be disease 
modifying. Statistical analysis 
included: one-way analysis of 
variance (ANOVA) followed by 
Newman-Keuls.  
 
Figure 13. Sepiapterin levels in DSS 
induced IBD and IBD mice treated 
with QM385. Sepiapterin acts as an on 
target biomarker for Spr inhibition. In 
naive control C57 mice as well as mice 
treated only with 2% DSS for 6 days 
then QM385 or vehicle from day 7-9. 
Mice not treated with QM385 
demonstrated no evidence of plasma 
sepiapterin on Day 9 (Vehicle).  Mice 
treated with QM-385 (0.3, 1, 3 mg/kg) 
demonstrated a dose responsive 
increase in plasma sepiapterin levels. 
These data demonstrate that Spr is 
being successfully inhibited with 
QM385 treatment in a dose responsive manner. Statistical analysis included: one-way 
analysis of variance (ANOVA) followed by Tukey's multiple comparisons post-hoc test. 
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Figure 14. Dual Immunoreactivity of Serotonin and Gch1 in distal colon of eGFP- 
Gch1 mice. While control (A) mice did not received any DSS followed by three-day 
treatment of vehicle, B) and C) mice received six days of 2% DSS followed by three-day 
treatment of either vehicle (B) or 3mg/kg QM385 (C). All 10-μm transverse cryosections 
were obtained for each condition (A, B, and C) from eGFP-Gch1 Swiss Webster mice and 
were assessed for dual immunoreactivity of serotonin and eGFP-GCH. Sections were 
exposed to primary, goat anti-serotonin (5-HT) (red) antibody (1:500, Immunostar), and 








The Establishment of the DSS-Induced IBD Model  
The DSS-induced IBD model has been one of the most commonly utilized animal 
models of human IBD this is because it closely epitomizes this disease in its morphology 
and symptomology. This allows a relatively simple and well controlled way to examine 
IBDs pathogenesis and develop novel therapeutics (Ghattamaneni et al., 2019; Okayasu et 
al., 1990). In this study, we have successfully implemented the DSS induced IBD model 
in mice evidenced by the DAI data, morphological changes, and mechanical 
hypersensitivity.  
Consistent with previous data, we have demonstrated that by four days of DSS 
treatment, there was a significant increase clinical symptoms of inflammation, such as 
weight loss, diarrhea and bloody stools (Figure 5), changes which start as early as just one 
day after treatment and progress successively (Chassaing et al., 2014; Malik et al., 2016). 
These changes result from damage and increased permeability to the epithelial layer of the 
intestinal lining and to the mucus membrane that normally protects this surface; damage to 
these barriers facilitate the entry of proinflammatory intestinal contents (Chassaing et al., 
2014; Malik et al., 2016). Our data reflect the changes observed in IBD patients where 
continual intestinal damage and inflammation result in the same clinical symptoms as 
witnessed in the mice (Chassaing et al., 2014). In addition thinning and shortening of the 
colon in IBD is also associated with the weight loss and rectal bleeding (Chassaing et al., 
2014), which we also demonstrate as a result of the inflammatory process (Figure 12). 
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We have also successfully shown that referred visceral abdominal pain (Figure 6) 
statistically increased as a result of intestinal inflammation. The increases in mechanical 
hypersensitivity of the abdomen was evidenced by an increase in von Frey hair sensitivity 
that was significantly present at 2 days and as early as one day after 6 days of DSS treatment 
(Figure 6). These early changes are consistent with acute pain being an early sign of tissue 
damage, which later as high levels of sensitivity develop (4 days on), these symptoms 
become more pathological and chronic. Such symptoms behavioral data are consistent with 
previous DSS results (Eijkelkamp et al., 2007; Kozlowski et al., 2013).  
At 7 days following six days of DSS treatment, clear microscopic symptoms of 
epithelial loss, decrease of crypt integrity and increase of inflammatory infiltration were 
observed (Figure 7). Others have tested different concentrations of DSS in the drinking 
water (usually ranging between 2-5% and in some cases as high as 10%) (Okayasu et al., 
1990). As our primary goal is to study abdominal pain hypersensitivity with attendant 
colonic inflammation, each of which are markedly and significantly and present in this 
dosing protocol (2% for 6 days), we believe that this protocol is a reasonable balance 
between animal welfare and reliable disease initiation (Malik et al., 2016). It should be 
noted that the top of the DAI scale is 12 and we achieve a maximum of 4 with this dosing 
protocol. 
 
BH4 Pathway and the DSS-Induced IBD Model 
We utilized the DSS-induced IBD model to examine the involvement of the BH4 
pathway and of EC cells in the development and progression of IBD. A chronically 
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activated immune system significantly contributes to the intestinal inflammatory response 
in patients with IBD (Choy et al., 2017; Zhang, 2014). In patients with IBD, there are 
increased levels of CD68 macrophages that secrete proinflammatory cytokines like TNF-
α, which functions as a signaling molecule for both innate (macrophages) and adaptive (T-
cells) immune systems (Caprioli et al., 2013; Choy et al., 2017; Zhang, 2014). The 
functional upregulation of CD68 and TNF-α in the pathogenesis of IBD was evidenced in 
our study with significant gene expression in DSS treated colon at 7 days with a 3.4-fold 
increase in CD68 and 3.5-fold increase in TNF-α (Figure 9). Antigen presenting cells, such 
as macrophages and dendritic cells, activate T-cells of the adaptive immune system (Shin 
et al., 2018); this was also demonstrated in our study with a 4.2-fold upregulation of CD4 
gene expression as a result of DSS treatment (Figure 9). The greater fold increase in CD4 
compared to the other pro-inflammatory mediators further validates the fact that CD4 
positive T cells are largely implicated a cause of the chronic inflammation present IBD 
(Shin et al., 2018). Taken together, CD4 T cells is the major contributing factor of the clear 
microscopic symptoms (Figure 7) and is associated with high levels of referred visceral 
abdominal pain hypersensitivity (Figure 6). For future directions, it would be interesting 
to stain or label immunohistochemically for CD68 and CD4 in colon tissue to demonstrate 
the association of macrophages and T cells respectively with other cells, such as EC cells, 
in the inflamed colon. 
The immune system also likely plays an important role in the function of EC cells 
- with products from CD4 T cells and macrophages, among other immune cells, activating 
EC cells through toll like receptors and other complexes to cause an increase production of 
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5-HT (Khan, 2013). EC cells modulate sensory neurons by acting as gatekeepers, 
transducing information between the intestinal lumen and the sensory nervous system. This 
signaling can occur, for instance, via the activation of EC cells receptors on the luminal 
surface, such TrpA1, leading to the release of EC cell neurotransmitters, such as 5-HT 
(Bellono et al., 2017; Breit et al., 2018). In colon biopsies of patients with IBD, there is a 
significant upregulation in TRPA1(Kun et al., 2014), which we have also mirrored in our 
data in DSS treated mice (Figure 9) along with the increase in serotonin immunoreactivity 
with DSS treatment (Figure 14B), which is also present in patients (Kim et al., 2015). 
While TrpA1 is expressed in sensory neurons in dorsal root, trigeminal, and nodose ganglia 
(Kun et al., 2014), only colon tissue was analyzed in these studies, so here TrpA1, as well 
as 5HT, are good markers of activated EC cells following DSS treatment. TrpA1 has also 
been shown to cause mechanical hypersensitivity in colitis naïve uninflamed bowel tissue 
(Brierley et al., 2009). Since the upregulation of TrpA1 receptor gene expression in the 
colon (Figure 9) occurred alongside an increase in referred visceral pain (Figure 6), pain 
associated with IBD could be a result of an augmentation of EC cells function, through 
TrpA1 expression, for instance, but likely many receptor systems create this activation. 
Along with the increase in 5HT immunoreactivity in EC cells, we saw an 
upregulation of eGFP immunoreactivity for Gch1 after DSS treatment (Figure 14B). This 
finding along with the upregulation in the gene expression of Gch1 and Spr (i.e. BH4 
pathway) in DSS-induced IBD colons (Figure 9) are novel additions to DSS-induced IBD 
research. Since we demonstrate an increase in Gch1 in EC cell like profiles in the DSS 
colon (Figure 14B), we assume that at least some of the upregulated colonic Spr 
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transcription is EC cell derived. In a previous study, active macrophages have been shown 
to produce excess BH4 (Latremoliere et al., 2015), which also points to the pathway’s 
involvement in IBD through increases CD68 positive macrophage action (Latremoliere et 
al., 2015). In more recent publications, our lab has shown that the BH4 pathway is an 
essential key regulator for T-cell proliferation (Cronin et al., 2018), which now with our 
current results makes BH4 a key regulator for the pathogenesis of IBD. Therefore, here we 
suggest that an upregulation of Gch1 and Spr (i.e. the BH4 synthesis pathway) may also be 
present in human IBD. This would be supported by the efficacy of SSZ (a SPR inhibitor) 
in IBD. For future directions, to further confirm the origin of the upregulated Gch1 and 
Spr, additional experiments, such as immunostaining or in situ hybridization, are necessary. 
We are currently in the process of counting EC cell derived serotonin and EC cell derived 
Gch1 in DSS treated colons to further solidify the pathway’s involvement in the 
pathogenesis of IBD.  
We also demonstrate an upregulation of neopterin levels following 6 days of DSS 
treatment, measurements taken on day 7 (Figure 8); these data prove that the BH4 de novo 
synthesis pathway is upregulated within the mouse inflamed colon. Neopterin is a stable 
by product of the BH4 synthesis cascade and therefore demonstrates the engagement the 
de novo pathway (Figure 15). Multiple studies, such as those by Latremoliere et al. (2015) 
and Tegeder et al. (2006), have shown an increase pain hypersensitivity along with an 
increase in tissue BH4. Interestingly, neopterin is not only a biomarker of the BH4 de novo 
pathway synthesis, but it is also a biomarker for active chronic inflammation in humans 
(Husain et al., 2013). This mechanism has been linked to the release of neopterin from 
 
47 
macrophages is stimulated mainly by IFN-γ (from TH1-driven activated CD4 T cells), but 
also by other proinflammatory mediators, such as TNF- α or IL-1β (Nancey et al., 2013). 
Elevated levels of neopterin is seen in patients with autoimmune disorders, such as 
rheumatoid arthritis, or bacterial and viral infections, such as HIV, all of which elicit an 
inflammatory immune response (Murr et al., 2002). Patients with IBD have elevated levels 
of both proinflammatory mediators, such as TNF-α and IFN-𝛾 (Cader and Kaser, 2013; de 
Mattos et al., 2015) and neopterin, which have been shown to correlate with the severity 
of intestinal mucosal lesions in IBD (Husain et al., 2013). In fact, active IBD has 
significantly higher levels of neopterin than the inactive form (Lehmann et al., 2015). This 
all aligns with what we have shown in our study, where there is a significant increase of 
neopterin in DSS treated colons (Figure 8). Therefore, as a result of DSS-induced IBD, 
the BH4 synthesis pathway is activated likely due to inflammation (release pro-
inflammatory mediators), and we now suggest that at least part of this increase is due to 
EC cell activation. For future experiments, since the levels of neopterin correlate with the 
severity of colitis (Lehmann et al., 2015), we will collect neopterin daily from urine or 
fecal matter to assess the severity of IBD and the effects of treatment, such as QM385, on 
induction and maintenance therapy of IBD.  
To assay the function of our SPR inhibitor, QM385, we quantified concentrations 
sepiapterin within the plasma of DSS treated mice. There were no changes in sepiapterin 
as a result of DSS treatment (Figure 13); however, sepiapterin was observed after QM385 
treatment at concentrations that mirrored the dosing of QM385. In 2015, while examining 
the inhibitory effects of other SPR inhibitors on the reduction of neuropathic and 
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inflammatory pain, our lab observed a correlation between SPR inhibition and sepiapterin 
levels (Latremoliere et al., 2015). As seen in Figure 1, in pathological inflammatory and 
chronic pain states, Gch1 is upregulated resulting in an over-production of BH4 
(Latremoliere and Costigan, 2011; Latremoliere et al., 2015). While inhibiting Spr allows 
for the blockage of BH4 via the de novo pathway, physiological levels of BH4 are still 
maintained by other enzymes in the salvage pathway that take over the role for Spr 
(Latremoliere and Costigan, 2011).  
An effective treatment for IBD is SSZ (a SPR inhibitor) and MTX, (a DHPR inhibitor) 
(Neurath, 2017), which suggests treatment of IBD through the inhibition of BH4. In 
demonstrating that the BH4 pathway is an essential key regulator for T-cell proliferation, 
Cronin et al. (2018) used QM385, our novel SPR inhibitor, to block the proliferation of 
human CD4 T cells (Cronin et al., 2018). QM385 simulated the same inhibitory effects 
as SPRi3 (another SPR inhibitor), but at a lower concentration, minimizing the side 
effects (Cronin et al., 2018). Furthermore, SPRi3 is a better BH4 synthesis cascade 
inhibitor than SSZ (Cronin et al., 2018; Latremoliere et al., 2015). Given all this, QM385 
was used in our DSS experiments as a stronger, more specific and more effective 
alternative to SSZ and it demonstrated a dose responsive increase in plasma sepiapterin 
levels proving its role in inhibiting BH4 synthesis in DSS induced colitis (Figure 13). 
Therefore, QM385 is successfully engaging Spr and therefore inhibiting BH4 synthesis in 
a dose responsive manner with 3 mg/kg proving to give the best response, when measured 




Dual Action of BH4 Inhibition (with QM385) on DSS-Induced IBD  
With QM385 treatment of DSS-induced IBD, there is a slight recovery of the 
elevated DAI observed with DSS treatment at Day 9 (after 3 days of QM385 treatment); 
however, this was not significant and improvements in DAI score were not dose dependent 
(Figure 10). For future experiments, more animals may result in these data achieving 
significance, but also intrinsic variation in this measure may be too high, and as a result 
this measure may not be a reliable measure of the effects of QM385 action. However, our 
data on QM385 altering abdominal hypersensitivity and colon length does suggest that 
QM385 slowed down the progression of the inflammatory response in IBD and even 
hastened the reversal of DSS effects.  
Since shortening of the colon in IBD is associated with clinical and microscopic symptoms 
such as weight loss and rectal bleeding (Chassaing et al., 2014), this data suggests that 
QM385 may be disease modifying (i.e. could lead to disease remission in patients). Further 
experiments are necessary to examine any effects of QM385 on long-term IBD in mice, to 
fully assay chronic disease symptoms. 
 Cronin et al. (2018) showed that BH4 is necessary for T cell proliferation; 
therefore, QM385, in inhibiting BH4 synthesis, will decrease T cell proliferation, which 
would be expected to significantly reduce intestinal inflammatory response in IBD in 
patients (Choy et al., 2017; Zhang, 2014). QM385’s role in alleviating the immune 
response in DSS-induced IBD was evident with the improvements in the macroscopic 
clinical symptoms of inflammation (Figure 10) and recovery in colon length (Figure 12). 
QM385 can also inhibit macrophages’ ability to produce excess nitric oxide, which again 
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will reduce sensory signaling and ongoing inflammation (Latremoliere et al., 2015). To 
further validate QM385’s anti-inflammatory behavior, in future experiments, we will 
examine CD4, CD68 and TNF-α gene expression and immunostaining, assess the 
histological changes (i.e. microscopic lesions), and quantify neopterin levels. Moreover, to 
further explore the role of BH4 signaling in colitis, we can conditionally over-express Gch1 
in EC cells, T cells or potentially both, which should result in a worsening of IBD 
symptoms. Conversely, we can knock-out Gch1 expression in T cells and treat mice with 
DSS, which should reduce IBD symptoms in an analogous way to the results of Cronin et 
al (2018) that demonstrated this action in the T-cell supplementation model of IBD.  
QM385 alleviated the inflammatory response (at 3 mg/kg), but also demonstrated 
a significant improvement in referred visceral abdominal pain at 1 and 3 mg/kg (Figure 
11). Moreover, QM385 appears to largely resolve the upregulation of serotonin and eGFP 
(Gch1) immunoreactivity in the distal colon after DSS treatment (Figure 14 C versus B). 
To quantify the effects of QM385 on activation of EC cells, we are currently counting the 
number of cells with serotonin and GCH1 immunoreactivity in each condition. As 90% of 
the body’s 5-HT is produced in by EC cells (Park et al., 2016) and BH4 is an essential co-
factor for 5-HT synthesis, we hypothesize that inhibiting this pathway will have profound 
effects on EC cell biology and therefore abdominal pain due to IBD. Here, we show that 
QM385 suppresses the BH4 pathway in EC cells (i.e. suppress EC cell activation), by 
causing, we assume, less serotonin production and therefore, less activation of the gut 
sensory neurons (Figure 14). We intend to conditionally knock-out Gch1 in EC cells 
examine the specific action of this cellular cascade in IBD. Potential proof of 5HT signaling 
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from EC cells causing hypersensitivity in patients is evidenced by 5HT3 receptor 
antagonists, such as Alosetron and Cilansetron, that attenuate visceral pain by preventing 
the activation of these serotonin receptors expressed on sensory afferent neurons (Fayyaz 
and Lackner, 2008). Moreover, reducing 5-HT has been shown to delay induction of IBD, 
reduce severity of colitis, and decrease proinflammatory mediators (Kim et al., 2015).   
Collectively, our studies and those of others suggest a dual action of QM385 by 
1) Alleviating inflammation through targeting T cell proliferation / macrophage action 
and 2) Quashing abdominal pain by targeting EC cell activation, resulting in less 
serotonin, and therefore less pain signaling. Moreover, since double drug therapies have 
already proved successful in in IBD patients, using SSZ and anti-TNF biologics for 
instance (Herfarth, 2016; Neurath, 2017). Here we propose that QM385, may act to reduce 
IBD symptoms by simultaneously reducing ongoing inflammation and by reducing EC cell 







Figure 15. The Dual Actions of QM385 treatment on DSS-Induced IBD. A dual 
action of QM385 by 1) Alleviating inflammation through targeting T cell proliferation / 
macrophage action and 2) Quashing abdominal pain by targeting EC cell activation, 
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